Quantum Genomics announced it is strengthening its intellectual property around aminopeptidase A inhibitors with the granting of new patents protecting its second drug-candidate, QGC606. The US Patent and Trademark Office (USPTO) has sent Quantum Genomics its agreement to grant patent rights resulting from application US 17/437,862 filed on September 10th, 2021. The Australian Patent Office validated the grant of patent AU2020235216 without amending the application filed on August 17th, 2021.

These two new patents protect QGC606 in the United States and Australia until March 2040, a new chemical series of inhibitors of cerebral aminopeptidase A and more particularly the drug-candidate QGC606, as well as any pharmaceutical composition including any of these inhibitors as an active ingredient, for a therapeutic use in the treatment of cardiovascular diseases.